Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zuclomiphene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 10/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | EBP | Q15125 | 5/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enclomiphene SCHEMBL8040981 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Clomiphene SCHEMBL220953 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Clomiphene SCHEMBL20942789 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Clomiphene SCHEMBL27599894 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Enclomiphene SCHEMBL220459 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8616232 | 0.94 | KMT2A (0.89) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8614802 | 0.94 | KMT2A (0.89) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8614814 | 0.94 | KMT2A (0.89) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8612826 | 0.93 | KMT2A (0.87) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8613135 | 0.93 | KMT2A (0.87) | KDM4EKMT2ACYP2D6MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661396-B2 | Crystalline forms of zuclomiphene citrate | APOTEX INC. (CA) | 2023-05-30 | — | — | US | claimed |
| EP-4146620-A1 | PROCESSES FOR THE PRODUCTION OF ISOMERICALLY PURE OR ENRICHED CIS-CLOMIPHENE | PCAS (FR) | 2023-03-15 | — | — | EP | claimed |
| US-11572333-B2 | Processes for the production of isomerically pure or enriched cis-clomiphene | PCAS (FR) | 2023-02-07 | — | — | US | claimed |
| US-11440871-B2 | Zuclomiphene salts and crystalline forms thereof | APOTEX INC. (CA) | 2022-09-13 | — | — | US | claimed |
| WO-2021224184-A1 | PROCESSES FOR THE PRODUCTION OF ISOMERICALLY PURE OR ENRICHED CIS-CLOMIPHENE | PCAS (FR) | 2021-11-11 | — | — | WO | claimed |
| EP-3907213-A1 | PROCESSES FOR THE PRODUCTION OF ISOMERICALLY PURE OR ENRICHED CIS-CLOMIPHENE | PCAS (FR) | 2021-11-10 | — | — | EP | claimed |
| US-20210340096-A1 | PROCESSES FOR THE PRODUCTION OF ISOMERICALLY PURE OR ENRICHED CIS-CLOMIPHENE | PCAS (FR) | 2021-11-04 | — | — | US | claimed |
| US-20210221767-A1 | Crystalline Forms of Zuclomiphene Citrate | THE BANK OF NOVA SCOTIA (CA) | 2021-07-22 | — | — | US | claimed |
| US-20210147338-A1 | Zuclomiphene Salts and Crystalline Forms Thereof | THE BANK OF NOVA SCOTIA (CA) | 2021-05-20 | — | — | US | claimed |
| US-10758500-B2 | Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene | ASPEN PARK PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | claimed |
| EP-1216024-B1 | FORMULATION FOR MENOPAUSAL WOMEN | DRUGTECH CORP (US) | 2007-03-21 | — | — | EP | claimed |
| EP-1216024-A4 | FORMULATION FOR MENOPAUSAL WOMEN | DRUGTECH CORP (US) | 2005-02-02 | — | — | EP | claimed |
| US-20020173510-A1 | Formulation for menopausal women | DRUGTECH CORPORATION | 2002-11-21 | — | — | US | claimed |
| US-6479545-B1 | Formulation for menopausal women | DRUGTECH CORPORATION | 2002-11-12 | — | — | US | claimed |
| US-20020137749-A1 | Formulation for menopausal women | DRUGTECH CORPORATION (US) | 2002-09-26 | — | — | US | claimed |
| EP-1216024-A1 | FORMULATION FOR MENOPAUSAL WOMEN | Drugtech Corporation (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001024772-A1 | FORMULATION FOR MENOPAUSAL WOMEN | DRUGTECH CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| EP-0178862-B1 | ANTIESTROGEN THERAPY FOR SYMPTOMS OF ESTROGEN DEFICIENCY | BCM Technologies, INC. (US) | 1993-08-04 | — | — | EP | claimed |
| US-4729999-A | MENOPAUSE, SIDE EFFECT PREVENTION | BCM TECHNOLOGIES (US) | 1988-03-08 | — | — | US | claimed |
| EP-0178862-A2 | Antiestrogen therapy for symptoms of estrogen deficiency | BCM Technologies, INC. (US) | 1986-04-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221767-A1 | Crystalline Forms of Zuclomiphene Citrate | CYP11A1, APOL1, APOB | ESR1 1538/4885KDM4E 3582/4885KMT2A 3608/4885 |
| US-11661396-B2 | Crystalline forms of zuclomiphene citrate | CYP11A1, APOL1, APOB | ESR1 1538/4885KDM4E 3582/4885KMT2A 3608/4885 |
| US-11440871-B2 | Zuclomiphene salts and crystalline forms thereof | ZP1, ZYX, ALPP | ESR1 20/4885KDM4E 2518/4885KMT2A 1497/4885 |
| US-20020137749-A1 | Formulation for menopausal women | SHBG, FABP6, BRCA1 | ESR1 17/4885KDM4E 3618/4885KMT2A 3096/4885 |
| US-20020173510-A1 | Formulation for menopausal women | SHBG, FABP6, BRCA1 | ESR1 17/4885KDM4E 3618/4885KMT2A 3096/4885 |
| US-20210147338-A1 | Zuclomiphene Salts and Crystalline Forms Thereof | ZP1, ZYX, ALPP | ESR1 20/4885KDM4E 2484/4885KMT2A 1441/4885 |
| US-10758500-B2 | Treating androgen deprivation therapy induced hot flashes and bone loss in men using cis-clomiphene | ACP3, SHBG, NR5A1 | ESR1 52/4885KDM4E 867/4885KMT2A 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.